Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...
Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
MedPage Today on MSN
Regimen improves PFS in highly mutated metastatic colorectal cancer
But is the combination a "viable alternative" to nivolumab and ipilimumab?
J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO conference.
MD Anderson studies reveal how cancer cells rewire metabolism to spread. A glucose–fructose mix promotes colorectal ...
4don MSN
Fewer young adults are dying from the leading causes of cancer death — except colorectal cancer
The researchers examined the five leading causes of cancer death among the under-50 age group. They found that overall, from 1990 through 2023, more than 1.2 million people died of cancer in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results